Jun Ma1, Xiao-Long Zhang2, Cheng-Yu Wang3, Zhi Lin3, Jie-Ru Tao3, Hua-Cheng Liu3. 1. Department of Neurosurgery, Shaoxing Central Hospital Shaoxing, 312003, China. 2. Department of Intensive Care Unit, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University Wenzhou, 325027, China. 3. Department of Anesthesiology, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University Wenzhou, 325027, China.
Abstract
OBJECTIVE: To investigate the neuro-protective effects of dexmedetomidine (dex) on I/R-induced spinal injury and potential mechanisms. METHODS: sprague-Dawley rats in the treatment group received intraperitoneal injections of 25 mg/kg dexmedetomidine, MC stabilizer cromolyn (100 mg/kg), MCs stimuliser compound 48/80 (80 mg/kg), PBS at 24 h befor IR. Underwent 5 minutes of aortic occlusion via median sternotomy, functional scores were recorded at 12, 24, 36 and 48 hours after reperfusion. Additionally, 3 mice underwent sham surgery with sternotomy and dissection of the aorta and subclavian artery with no occlusion. Spinal cords were examined for protein kinase B (AKT), CREB, and brain-derived neurotrophic factor (BDNF) following treatment alone or ischemia-reperfusion surgery. Collected the serum to observe the expression of pro-inflammation cytokines (TNF-α, INF-γ and IL-1β) and anti-inflammation cytokines (TGF-β, IL-10 and IL-6). Then the MCs were harvested to test the expression surface molecular of FcεR and MCs' degranulation. RESULTS: Pretreated the rats with dexmedetomidine has higher neurologic function at all time points after I/R injury. We collected the serum of rats then detected the pro-inflammation cytokines TNF-α, INF-γ and IL-1β levels and anti-inflammation cytokinses TGF-β, IL-10 and IL-6 levels, found that the pro-inflammation cytokines of dexmedetomidine group was decreased whereas the anti-inflammation cytokinses was increased. At the same time the protect protein of AKT, CREB and mRNA BDNF were increased. They had the same results with cromolyn group, and opposite with the compound 48/80 group. We pretreated MCs with dexmedetomidine in vitro, and found that the activity surface molecular of MCs was down-regulation, and MCs degranulation was decreased. CONCLUSION: We thus demonstrate a possible mechanism by which dexmedetomidine alleviates spinal cord I/R injury through blocking the MCs degranulation.
OBJECTIVE: To investigate the neuro-protective effects of dexmedetomidine (dex) on I/R-induced spinal injury and potential mechanisms. METHODS:sprague-Dawley rats in the treatment group received intraperitoneal injections of 25 mg/kg dexmedetomidine, MC stabilizer cromolyn (100 mg/kg), MCs stimuliser compound 48/80 (80 mg/kg), PBS at 24 h befor IR. Underwent 5 minutes of aortic occlusion via median sternotomy, functional scores were recorded at 12, 24, 36 and 48 hours after reperfusion. Additionally, 3 mice underwent sham surgery with sternotomy and dissection of the aorta and subclavian artery with no occlusion. Spinal cords were examined for protein kinase B (AKT), CREB, and brain-derived neurotrophic factor (BDNF) following treatment alone or ischemia-reperfusion surgery. Collected the serum to observe the expression of pro-inflammation cytokines (TNF-α, INF-γ and IL-1β) and anti-inflammation cytokines (TGF-β, IL-10 and IL-6). Then the MCs were harvested to test the expression surface molecular of FcεR and MCs' degranulation. RESULTS: Pretreated the rats with dexmedetomidine has higher neurologic function at all time points after I/R injury. We collected the serum of rats then detected the pro-inflammation cytokines TNF-α, INF-γ and IL-1β levels and anti-inflammation cytokinses TGF-β, IL-10 and IL-6 levels, found that the pro-inflammation cytokines of dexmedetomidine group was decreased whereas the anti-inflammation cytokinses was increased. At the same time the protect protein of AKT, CREB and mRNA BDNF were increased. They had the same results with cromolyn group, and opposite with the compound 48/80 group. We pretreated MCs with dexmedetomidine in vitro, and found that the activity surface molecular of MCs was down-regulation, and MCs degranulation was decreased. CONCLUSION: We thus demonstrate a possible mechanism by which dexmedetomidine alleviates spinal cord I/R injury through blocking the MCs degranulation.
Authors: J Pablo Abonia; Daniel S Friend; William G Austen; Francis D Moore; Michael C Carroll; Rodney Chan; Jalil Afnan; Alison Humbles; Craig Gerard; Pamela Knight; Yoshihide Kanaoka; Shinsuke Yasuda; Nasa Morokawa; K Frank Austen; Richard L Stevens; Michael F Gurish Journal: J Immunol Date: 2005-06-01 Impact factor: 5.422
Authors: Roy K Greenberg; Qingsheng Lu; Eric E Roselli; Lars G Svensson; Michael C Moon; Adrian V Hernandez; Joseph Dowdall; Marcelo Cury; Catherine Francis; Kathryn Pfaff; Daniel G Clair; Kenneth Ouriel; Bruce W Lytle Journal: Circulation Date: 2008-08-04 Impact factor: 29.690
Authors: Pratik P Pandharipande; Brenda T Pun; Daniel L Herr; Mervyn Maze; Timothy D Girard; Russell R Miller; Ayumi K Shintani; Jennifer L Thompson; James C Jackson; Stephen A Deppen; Renee A Stiles; Robert S Dittus; Gordon R Bernard; E Wesley Ely Journal: JAMA Date: 2007-12-12 Impact factor: 56.272
Authors: Marshall T Bell; Ferenc Puskas; Daine T Bennett; Paco S Herson; Nidia Quillinan; David A Fullerton; T Brett Reece Journal: J Thorac Cardiovasc Surg Date: 2013-09-13 Impact factor: 5.209
Authors: Jianteng Gu; Pamela Sun; Hailin Zhao; Helena R Watts; Robert D Sanders; Niccolo Terrando; Peiyuan Xia; Mervyn Maze; Daqing Ma Journal: Crit Care Date: 2011-06-24 Impact factor: 9.097